Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma-Reference-Cited by-同舟云学术

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

Published:2006-04-15 Issue:8 Volume:107 Page:3415-3416
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

van de Donk Niels W. C. J.,Kröger Nicolaus,Hegenbart Ute,Corradini Paolo,Miguel Jesus F. San,Goldschmidt Hartmut,Perez-Simon Jose A.,Zijlmans Mark,Raymakers Reinier A.,Montefusco Vittorio,Ayuk Francis A.,van Oers Marinus H. J.,Nagler Arnon,Verdonck Leo F.,Lokhorst Henk M.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/107/8/3415/1282044/zh800806003415.pdf

Reference8 articles.

1. Kroger N, Schwerdtfeger R, Kiehl, M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100: 755-760.

2. Maloney DG, Molina AJ, Sahebi, F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102: 3447-3454.

3. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102: 1115-1123.

4. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292: 895-902.

5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352: 2487-2498.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect;Hemato;2021-04-14

2. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation;Clinical Lymphoma Myeloma and Leukemia;2020-06

3. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution;European Journal of Haematology;2016-05-03

4. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity;Bone Marrow Transplantation;2016-01-04

5. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs;Expert Opinion on Biological Therapy;2015-04-12